A structure-based approach towards identification of inhibitory fragments for eleven-nineteen-leukemia protein (ENL) YEATS domain
D. Heidenreich, M. Moustakim, J. Schmidt, D. Merk, P. E. Brennan, O. Fedorov, A. Chaikuad, S. Knapp
Abstract
Lysine acetylation is an epigenetic mark that is principally recognized by bromodomains and recently structurally diverse YEATS domains also emerged as readers of lysine acetyl/acylations. Here we present a crystallography-based strategy and the discovery of fragments binding to the ENL YEATS domain, a potential drug target. Crystal structures combined with synthetic efforts led to the identification of a sub-micromolar binder, providing first starting points for the development of chemical probes for this reader domain family.
02 /Specification & Classification
Click any tag to browse matching papers- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Phage-Assisted, Active Site-Directed Ligand Evolution with a Genetically Encoded Nε-Butyryl-ʟ-Lysine to Identify a Cellularly Potent and Selective Inhibitor for the ENL YEATS Domain as an Anti-Leukemia Agent
P.-H. C. Chen, X. S. Guo, … W. R. Liu·bioRxiv·Jan 8, 2023
- Structural insights into interaction mechanisms of alternative piperazine-urea YEATS domain binders in MLLT1
X. Ni, D. Heidenreich, … A. Chaikuad·bioRxiv·Nov 9, 2019
- Conformational and Thermodynamic Differences Underlying Wild-type and Mutant ENL YEATS Domain Specificity for Epigenetic Marks
L. Baweja, J. Wereszczynski·bioRxiv·Jul 14, 2022
- Structure and inhibitor binding characterization of oncogenic MLLT1 mutants
X. Ni, A. T. Londregan, … A. Chaikuad·bioRxiv·Feb 8, 2021
- Chemical inhibition of ENL/AF9 YEATS domains in acute leukemia
L. Garnar-Wortzel, T. R. Bishop, … M. A. Erb·bioRxiv·Dec 1, 2020
- The Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Potential Drug Candidates to Treat Acute Myeloid Leukemia
X. S. Guo, P.-H. C. Chen, … W. R. Liu·bioRxiv·Dec 7, 2022